×
BioLineRx Common Stock Net 2012-2024 | BLRX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
BioLineRx common stock net from 2012 to 2024. Common stock net can be defined as the value of common equity ownership.
View More
BioLineRx Common Stock Net 2012-2024 | BLRX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
BioLineRx common stock net from 2012 to 2024. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.5B
Takeda Pharmaceutical (TAK)
$43.4B
Merck (MKKGY)
$21B
Astellas Pharma (ALPMY)
$20.3B
Sandoz Group AG (SDZNY)
$19.9B
United Therapeutics (UTHR)
$17.9B
Summit Therapeutics (SMMT)
$16.1B
Neurocrine Biosciences (NBIX)
$12.9B
Shionogi (SGIOY)
$12.3B
Catalent (CTLT)
$10.8B
Jazz Pharmaceuticals (JAZZ)
$7.7B
Madrigal Pharmaceuticals (MDGL)
$7.4B
Orion OYJ (ORINY)
$6.8B
Corcept Therapeutics (CORT)
$6.2B
Ionis Pharmaceuticals (IONS)
$6.1B
Crinetics Pharmaceuticals (CRNX)
$4.8B
PTC Therapeutics (PTCT)
$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.8B
Dyne Therapeutics (DYN)
$2.8B
Catalyst Pharmaceuticals (CPRX)
$2.8B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
Soleno Therapeutics (SLNO)
$2.6B
NewAmsterdam Pharma (NAMS)
$2.2B
Recursion Pharmaceuticals (RXRX)
$2.2B
Centessa Pharmaceuticals (CNTA)
$1.9B
Harrow (HROW)
$1.8B
Evotec AG (EVO)
$1.7B
Ocular Therapeutix (OCUL)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.7B
ARS Pharmaceuticals (SPRY)
$1.7B